NSD2: Nuclear Receptor Binding SET Domain Protein 2
A histone methyltransferase implicated in multiple myeloma, Wolf-Hirschhorn syndrome, and other cancers
Gene Information Card
| Symbol | NSD2 |
|---|---|
| Full Name | Nuclear receptor binding SET domain protein 2 |
| Gene Type | Protein coding |
| Chromosomal Location | 4p16.3 |
| NCBI Gene ID | 7468 ncbi.nlm.nih.gov/gene/7468 |
| Ensembl ID | ENSG00000109685 |
| UniProt ID | O96028 |
| OMIM ID | 602952 |
| HGNC ID | 12719 |
| Aliases | WHSC1, MMSET, TRX5, KMT3G, REIIBP |
Description
NSD2 (Nuclear Receptor Binding SET Domain Protein 2), also known as WHSC1 or MMSET, encodes a histone methyltransferase that primarily catalyzes dimethylation of histone H3 at lysine 36 (H3K36me2). This modification is critical for chromatin regulation, transcriptional elongation, and DNA repair. The gene is located in the Wolf-Hirschhorn syndrome critical region on chromosome 4p16.3. NSD2 is recurrently overexpressed or mutated in multiple myeloma due to t(4;14) translocations, and loss-of-function mutations cause Wolf-Hirschhorn syndrome. It is also implicated in various solid tumors and developmental disorders.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Multiple myeloma | t(4;14)(p16;q32) translocation leads to NSD2 overexpression, driving H3K36me2-mediated transcriptional reprogramming and proliferation | COSMIC, ClinVar, PMID: 21804562 |
| Wolf-Hirschhorn syndrome | Haploinsufficiency or loss-of-function mutations in NSD2 cause developmental delay, intellectual disability, and characteristic facial features | OMIM #194190, PMID: 15637732 |
| Acute lymphoblastic leukemia | NSD2 gain-of-function mutations (e.g., E1099K) increase H3K36me2 and promote leukemogenesis | COSMIC, PMID: 28346433 |
| Prostate cancer | NSD2 overexpression correlates with poor prognosis and androgen receptor signaling | PMID: 23563181 |
| Breast cancer | NSD2 amplification and overexpression linked to metastasis and tamoxifen resistance | PMID: 27507835 |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Testis | 15.2 | Medium |
| Bone marrow | 12.8 | Medium |
| Lymph node | 10.5 | Medium |
| Brain | 6.3 | Low |
| Liver | 4.1 | Low |
| Heart | 3.9 | Low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| K-562 (leukemia) | 18.7 | High expression |
| HeLa (cervical carcinoma) | 14.2 | Medium expression |
| HEK293 (embryonic kidney) | 12.1 | Medium expression |
| MCF7 (breast cancer) | 9.8 | Medium expression |
| HepG2 (liver cancer) | 7.5 | Low expression |
Data source:Human Protein Atlas(proteinatlas.org)
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| E1099K | Missense | ~5% in multiple myeloma | Gain-of-function; increases H3K36me2 activity |
| T1150A | Missense | ~2% in ALL | Gain-of-function; enhances methyltransferase activity |
| R1148W | Missense | Rare | Loss-of-function; disrupts SET domain |
| Whole gene deletion | Copy number loss | Wolf-Hirschhorn syndrome | Haploinsufficiency; developmental defects |
| t(4;14) fusion | Translocation | ~15% in multiple myeloma | Overexpression of NSD2; oncogenic driver |
Mutation functional classification
Loss of Function (LOF)
Deletions or missense mutations (e.g., R1148W) that reduce or abolish H3K36me2 activity, leading to Wolf-Hirschhorn syndrome phenotypes.
Gain of Function (GOF)
Missense mutations (e.g., E1099K, T1150A) that enhance methyltransferase activity, promoting oncogenesis in multiple myeloma and ALL.
Dominant Negative (DN)
Not well documented for NSD2; most reported mutations are either loss- or gain-of-function.
View complete mutation data:
Gene Ontology (GO)
| • nucleus (GO:0005634) | • protein binding (GO:0005515) |
| • histone-lysine N-methyltransferase activity (GO:0018024) | • histone methyltransferase activity (H3-K36 specific) (GO:0042800) |
| • chromatin organization (GO:0006325) | • regulation of transcription (GO:0006355) |
| • DNA damage response (GO:0006974) | • nucleoplasm (GO:0005654) |
Pathways
• Histone methylation (H3K36me2)
• Chromatin remodeling
• Transcriptional elongation by RNA polymerase II
• DNA double-strand break repair via homologous recombination
• Oncogenic signaling in multiple myeloma (t(4;14))
Protein Summary
NSD2 is a 1365-amino-acid nuclear protein containing a SET domain, PWWP domains, and PHD fingers. It functions as a histone methyltransferase that specifically dimethylates histone H3 at lysine 36 (H3K36me2), a mark associated with active transcription and chromatin accessibility. NSD2 interacts with nuclear receptors and transcription factors to regulate gene expression. Its overexpression due to t(4;14) translocation is a hallmark of a subset of multiple myeloma, while loss-of-function mutations cause Wolf-Hirschhorn syndrome. The protein also plays roles in DNA repair and development.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| NSD2 Knockout HEK293 Cell Line | EDJ-KQ3306 | Human | 7468 | Details Get a Quote |
| NSD2 Knockout A-549 Cell Line | EDJ-KQ24898 | Human | 7468 | Details Get a Quote |
| NSD2 Knockout HCT 116 Cell Line | EDJ-KQ24899 | Human | 7468 | Details Get a Quote |
| NSD2 Knockout HeLa Cell Line | EDJ-KQ24900 | Human | 7468 | Details Get a Quote |
Displaying Records 1 To 4 Of 4 Records